BG107596A - Фармацевтичен състав на салметерол и флутиказон пропионат - Google Patents

Фармацевтичен състав на салметерол и флутиказон пропионат Download PDF

Info

Publication number: BG107596A
Authority: BG; Bulgaria
Prior art keywords: salmeterol; fluticasone propionate; pharmaceutical formulation; physiologically acceptable; acceptable salt
Prior art date: 2000-08-31

Application number

BG107596A

Other languages

Bulgarian (bg)

English (en)

Inventor

Donald H. Horstman

Claire J. Maden

Original Assignee

Glaxo Group Limited

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-08-31

Filing date

2003-02-27

Publication date

2004-01-30

2003-02-27 Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited

2004-01-30 Publication of BG107596A publication Critical patent/BG107596A/bg

Links

WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 title claims abstract description 31
229960000289 fluticasone propionate Drugs 0.000 title claims description 27
239000008194 pharmaceutical composition Substances 0.000 title claims description 12
208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims abstract description 24
GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 claims description 32
150000003839 salts Chemical class 0.000 claims description 32
229960004017 salmeterol Drugs 0.000 claims description 31
229950000339 xinafoate Drugs 0.000 claims description 14
239000003814 drug Substances 0.000 claims description 8
238000000034 method Methods 0.000 claims description 7
229940124597 therapeutic agent Drugs 0.000 claims description 3
241000124008 Mammalia Species 0.000 claims description 2
239000003937 drug carrier Substances 0.000 claims description 2
238000004519 manufacturing process Methods 0.000 claims description 2
239000000546 pharmaceutical excipient Substances 0.000 claims description 2
238000002664 inhalation therapy Methods 0.000 claims 1
229940021597 salmeterol and fluticasone Drugs 0.000 abstract description 4
239000000203 mixture Substances 0.000 description 15
238000009472 formulation Methods 0.000 description 10
206010013975 Dyspnoeas Diseases 0.000 description 8
208000000059 Dyspnea Diseases 0.000 description 6
239000004480 active ingredient Substances 0.000 description 6
230000003862 health status Effects 0.000 description 6
230000006872 improvement Effects 0.000 description 6
230000000241 respiratory effect Effects 0.000 description 6
239000000843 powder Substances 0.000 description 5
239000000443 aerosol Substances 0.000 description 4
208000006673 asthma Diseases 0.000 description 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
229940124624 oral corticosteroid Drugs 0.000 description 4
239000000902 placebo Substances 0.000 description 4
229940068196 placebo Drugs 0.000 description 4
208000013220 shortness of breath Diseases 0.000 description 4
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 3
230000005713 exacerbation Effects 0.000 description 3
239000008101 lactose Substances 0.000 description 3
239000000047 product Substances 0.000 description 3
239000007921 spray Substances 0.000 description 3
208000024891 symptom Diseases 0.000 description 3
YFMFNYKEUDLDTL-UHFFFAOYSA-N 1,1,1,2,3,3,3-heptafluoropropane Chemical compound FC(F)(F)C(F)C(F)(F)F YFMFNYKEUDLDTL-UHFFFAOYSA-N 0.000 description 2
LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-tetrafluoroethane Chemical compound FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 description 2
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
208000037656 Respiratory Sounds Diseases 0.000 description 2
206010047924 Wheezing Diseases 0.000 description 2
239000000969 carrier Substances 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
239000013066 combination product Substances 0.000 description 2
229940127555 combination product Drugs 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000035475 disorder Diseases 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
230000004199 lung function Effects 0.000 description 2
239000003380 propellant Substances 0.000 description 2
230000009467 reduction Effects 0.000 description 2
229960002052 salbutamol Drugs 0.000 description 2
ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
LERNTVKEWCAPOY-DZZGSBJMSA-N tiotropium Chemical compound O([C@H]1C[C@@H]2[N+]([C@H](C1)[C@@H]1[C@H]2O1)(C)C)C(=O)C(O)(C=1SC=CC=1)C1=CC=CS1 LERNTVKEWCAPOY-DZZGSBJMSA-N 0.000 description 2
229940110309 tiotropium Drugs 0.000 description 2
DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
PDNHLCRMUIGNBV-UHFFFAOYSA-N 1-pyridin-2-ylethanamine Chemical compound CC(N)C1=CC=CC=N1 PDNHLCRMUIGNBV-UHFFFAOYSA-N 0.000 description 1
RTAPDZBZLSXHQQ-UHFFFAOYSA-N 8-methyl-3,7-dihydropurine-2,6-dione Chemical compound N1C(=O)NC(=O)C2=C1N=C(C)N2 RTAPDZBZLSXHQQ-UHFFFAOYSA-N 0.000 description 1
208000000884 Airway Obstruction Diseases 0.000 description 1
208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
206010006458 Bronchitis chronic Diseases 0.000 description 1
206010011224 Cough Diseases 0.000 description 1
239000004338 Dichlorodifluoromethane Substances 0.000 description 1
206010014561 Emphysema Diseases 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
206010062717 Increased upper airway secretion Diseases 0.000 description 1
229940121948 Muscarinic receptor antagonist Drugs 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
239000002253 acid Substances 0.000 description 1
239000000048 adrenergic agonist Substances 0.000 description 1
230000000172 allergic effect Effects 0.000 description 1
AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
230000001387 anti-histamine Effects 0.000 description 1
239000002260 anti-inflammatory agent Substances 0.000 description 1
229940124599 anti-inflammatory drug Drugs 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
239000000739 antihistaminic agent Substances 0.000 description 1
239000004599 antimicrobial Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
239000008135 aqueous vehicle Substances 0.000 description 1
208000010668 atopic eczema Diseases 0.000 description 1
239000002585 base Substances 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
206010006451 bronchitis Diseases 0.000 description 1
229940124630 bronchodilator Drugs 0.000 description 1
239000000337 buffer salt Substances 0.000 description 1
239000002775 capsule Substances 0.000 description 1
229910002092 carbon dioxide Inorganic materials 0.000 description 1
239000001569 carbon dioxide Substances 0.000 description 1
239000000812 cholinergic antagonist Substances 0.000 description 1
208000007451 chronic bronchitis Diseases 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
239000003246 corticosteroid Substances 0.000 description 1
229940124446 critical care medicine Drugs 0.000 description 1
229960000265 cromoglicic acid Drugs 0.000 description 1
201000009805 cryptogenic organizing pneumonia Diseases 0.000 description 1
230000034994 death Effects 0.000 description 1
231100000517 death Toxicity 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
229940042935 dichlorodifluoromethane Drugs 0.000 description 1
229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
VLARUOGDXDTHEH-UHFFFAOYSA-L disodium cromoglycate Chemical compound [Na+].[Na+].O1C(C([O-])=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C([O-])=O)O2 VLARUOGDXDTHEH-UHFFFAOYSA-L 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
229940112141 dry powder inhaler Drugs 0.000 description 1
230000002500 effect on skin Effects 0.000 description 1
230000000694 effects Effects 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
229960002714 fluticasone Drugs 0.000 description 1
MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 description 1
239000011888 foil Substances 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
230000004968 inflammatory condition Effects 0.000 description 1
229940125369 inhaled corticosteroids Drugs 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
OEXHQOGQTVQTAT-JRNQLAHRSA-N ipratropium Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 OEXHQOGQTVQTAT-JRNQLAHRSA-N 0.000 description 1
229960001888 ipratropium Drugs 0.000 description 1
239000007951 isotonicity adjuster Substances 0.000 description 1
239000007788 liquid Substances 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
239000003595 mist Substances 0.000 description 1
230000000510 mucolytic effect Effects 0.000 description 1
229960002259 nedocromil sodium Drugs 0.000 description 1
239000013618 particulate matter Substances 0.000 description 1
208000026435 phlegm Diseases 0.000 description 1
208000037821 progressive disease Diseases 0.000 description 1
208000023504 respiratory system disease Diseases 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
206010039083 rhinitis Diseases 0.000 description 1
229960005018 salmeterol xinafoate Drugs 0.000 description 1
238000007493 shaping process Methods 0.000 description 1
229940127211 short-acting beta 2 agonist Drugs 0.000 description 1
238000009097 single-agent therapy Methods 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000000243 solution Substances 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
-1 theophylline Chemical compound 0.000 description 1
229960000278 theophylline Drugs 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
229940029284 trichlorofluoromethane Drugs 0.000 description 1
229940070384 ventolin Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pulmonology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Emergency Medicine (AREA)
Otolaryngology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Treatment Of Water By Ion Exchange (AREA)

BG107596A 2000-08-31 2003-02-27 Фармацевтичен състав на салметерол и флутиказон пропионат BG107596A (bg)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US22938100P	2000-08-31	2000-08-31
PCT/GB2001/003928 WO2002017894A2 (en)	2000-08-31	2001-08-31	Pharmaceutical formulation of salmeterol and fluticasone propionate

Publications (1)

Publication Number	Publication Date
BG107596A true BG107596A (bg)	2004-01-30

Family

ID=22860986

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BG107596A BG107596A (bg)	2000-08-31	2003-02-27	Фармацевтичен състав на салметерол и флутиказон пропионат

Country Status (24)

Country	Link
US (1)	US20040009963A1 (es)
EP (1)	EP1313484A2 (es)
JP (1)	JP2004507494A (es)
KR (1)	KR20030031997A (es)
CN (1)	CN1449288A (es)
AP (1)	AP2003002753A0 (es)
AR (1)	AR030516A1 (es)
AU (1)	AU2001284236A1 (es)
BG (1)	BG107596A (es)
BR (1)	BR0113555A (es)
CA (1)	CA2420532A1 (es)
EA (1)	EA200300152A1 (es)
EC (1)	ECSP034487A (es)
HU (1)	HUP0303755A2 (es)
IL (1)	IL154403A0 (es)
MA (1)	MA25834A1 (es)
MX (1)	MXPA03001752A (es)
NO (1)	NO20030899L (es)
OA (1)	OA12370A (es)
PE (1)	PE20020387A1 (es)
PL (1)	PL365582A1 (es)
SK (1)	SK2302003A3 (es)
WO (1)	WO2002017894A2 (es)
ZA (1)	ZA200301475B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0106031D0 (en) *	2001-03-12	2001-05-02	Glaxo Group Ltd	Use
AU2003263717A1 (en) *	2002-09-25	2004-04-19	Astrazeneca Ab	A COMBINATION OF A LONG-ACTING Beta2-AGONIST AND A GLUCOCORTICOSTEROID IN THE TREATMENT OF FIBROTIC DISEASES
US20070071689A1 (en) *	2003-08-06	2007-03-29	Galephar M/F	Advantageous combination for inhalation of nacystelyn and bronchodilators
TR200907913A2 (tr) *	2009-10-20	2011-05-23	Bi̇lgi̇ç Mahmut	İnhalason yolu ile alınmak üzere kuru toz formunda farmasötik bileşim
US8834931B2 (en)	2009-12-25	2014-09-16	Mahmut Bilgic	Dry powder formulation containing tiotropium for inhalation
TR200909791A2 (tr) *	2009-12-25	2011-07-21	B�Lg�� Mahmut	Salmeterol ve flutikazon içeren farmasötik bileşim@
TR201000681A2 (tr) *	2010-01-29	2011-08-22	B�Lg�� Mahmut	İnhalasyon yoluyla alınan kuru toz formülasyonları.
US10111957B2 (en)	2012-07-05	2018-10-30	Arven Ilac Snayi ve Ticaret A.S.	Inhalation compositions comprising glucose anhydrous
US10105316B2 (en)	2012-07-05	2018-10-23	Arven llac Sanayi Ve Ticaret A.S.	Inhalation compositions comprising muscarinic receptor antagonist
WO2014007781A2 (en) *	2012-07-05	2014-01-09	Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi	Inhalation compositions
MX2015015132A (es) *	2013-04-29	2016-02-18	Sanofi Sa	Composiciones farmaceuticas inhalables y los dispositivos inhaladores que las contienen.
MA41378A (fr) *	2015-01-20	2017-11-28	Teva Branded Pharmaceutical Prod R & D Inc	Inhalateur de poudre sèche comprenant du propionate de fluticasone et du xinafoate de salmétérol
GB202202297D0 (en)	2022-02-21	2022-04-06	Verona Pharma Plc	Formulation production process
CA3263546A1 (en) *	2022-08-08	2024-02-15	Verona Pharma Limited	ENSIFENTRINE (RPL-554) FOR THE TREATMENT OF MODERATE CHRONIC OBSTRUCTIVE PULMONARY DISEASE
CN121620356A (zh)	2023-06-26	2026-03-06	维罗纳制药公司	包含恩塞芬汀的颗粒组合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL104068A (en) *	1991-12-12	1998-10-30	Glaxo Group Ltd	Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant
GB9808802D0 (en) *	1998-04-24	1998-06-24	Glaxo Group Ltd	Pharmaceutical formulations
GB9924992D0 (en) *	1999-10-21	1999-12-22	Glaxo Group Ltd	Pharmaceutical aerosol formulations
US20030032632A1 (en) *	1999-12-24	2003-02-13	Crispps Leslie Alan	Pharmaceutical aerosol formulation of salmeterol and fluticasone propionate

2001
- 2001-08-29 AR ARP010104122A patent/AR030516A1/es unknown
- 2001-08-29 PE PE2001000867A patent/PE20020387A1/es not_active Application Discontinuation
- 2001-08-31 WO PCT/GB2001/003928 patent/WO2002017894A2/en not_active Ceased
- 2001-08-31 JP JP2002522868A patent/JP2004507494A/ja active Pending
- 2001-08-31 AP APAP/P/2003/002753A patent/AP2003002753A0/en unknown
- 2001-08-31 IL IL15440301A patent/IL154403A0/xx unknown
- 2001-08-31 MX MXPA03001752A patent/MXPA03001752A/es unknown
- 2001-08-31 SK SK230-2003A patent/SK2302003A3/sk unknown
- 2001-08-31 EA EA200300152A patent/EA200300152A1/ru unknown
- 2001-08-31 CN CN01814708A patent/CN1449288A/zh active Pending
- 2001-08-31 BR BR0113555-4A patent/BR0113555A/pt not_active Application Discontinuation
- 2001-08-31 EP EP01963205A patent/EP1313484A2/en not_active Withdrawn
- 2001-08-31 AU AU2001284236A patent/AU2001284236A1/en not_active Abandoned
- 2001-08-31 US US10/363,438 patent/US20040009963A1/en not_active Abandoned
- 2001-08-31 PL PL01365582A patent/PL365582A1/xx not_active Application Discontinuation
- 2001-08-31 CA CA002420532A patent/CA2420532A1/en not_active Abandoned
- 2001-08-31 KR KR10-2003-7002890A patent/KR20030031997A/ko not_active Withdrawn
- 2001-08-31 OA OA1200300054A patent/OA12370A/en unknown
- 2001-08-31 HU HU0303755A patent/HUP0303755A2/hu unknown
2003
- 2003-02-20 EC EC2003004487A patent/ECSP034487A/es unknown
- 2003-02-24 ZA ZA200301475A patent/ZA200301475B/en unknown
- 2003-02-26 NO NO20030899A patent/NO20030899L/no not_active Application Discontinuation
- 2003-02-27 BG BG107596A patent/BG107596A/bg unknown
- 2003-02-27 MA MA27058A patent/MA25834A1/fr unknown

Also Published As

Publication number	Publication date
PL365582A1 (en)	2005-01-10
EA200300152A1 (ru)	2003-08-28
SK2302003A3 (en)	2003-08-05
WO2002017894A2 (en)	2002-03-07
AR030516A1 (es)	2003-08-20
KR20030031997A (ko)	2003-04-23
NO20030899D0 (no)	2003-02-26
ZA200301475B (en)	2004-05-24
IL154403A0 (en)	2003-09-17
MA25834A1 (fr)	2003-07-01
OA12370A (en)	2004-03-19
US20040009963A1 (en)	2004-01-15
HUP0303755A2 (hu)	2004-04-28
PE20020387A1 (es)	2002-06-24
AU2001284236A1 (en)	2002-03-13
CN1449288A (zh)	2003-10-15
NO20030899L (no)	2003-04-28
JP2004507494A (ja)	2004-03-11
ECSP034487A (es)	2003-03-31
MXPA03001752A (es)	2003-06-04
CA2420532A1 (en)	2002-03-07
BR0113555A (pt)	2003-07-22
WO2002017894A3 (en)	2002-08-08
EP1313484A2 (en)	2003-05-28
AP2003002753A0 (en)	2003-06-30

Publication	Publication Date	Title
KR100234864B1 (ko)	1999-12-15	기도 및 폐질환을 치료하기 위한 모메타손푸로에이트 약제
US20030113269A1 (en)	2003-06-19	Medical combinations comprising tiotropium and fluticasone proprionate
US20030119859A1 (en)	2003-06-26	Medical combinations comprising tiotropium and rofleponide
US20030109510A1 (en)	2003-06-12	Medical combinations comprising formoterol and budesonide
US20030139383A1 (en)	2003-07-24	Medical combinations comprising tiotropium and mometasone
WO2001078745A1 (en)	2001-10-25	Medical combinations comprising formoterol and fluticasone proprionate
AU2002334126B2 (en)	2005-12-15	Pharmaceutical combinations comprising salmeterol and fluticasone proprionate for the treatment of asthma
US20040009963A1 (en)	2004-01-15	Use of salmeterol and fluticasone propionate combination
AU2002334126A1 (en)	2003-07-03	Pharmaceutical combinations comprising salmeterol and fluticasone proprionate for the treatment of asthma
US20030114537A1 (en)	2003-06-19	Medical combinations comprising mometasone and salmeterol
WO2001078744A1 (en)	2001-10-25	Medical combinations comprising formoterol and mometasone
WO2001078738A1 (en)	2001-10-25	Medical compositions comprising (r,r)-formoterol and rofleponide
US20030096874A1 (en)	2003-05-22	Respiratory compositions
US20040019025A1 (en)	2004-01-29	Medical compositions comprising (r,r)-formoterol and rofleponide
JP5220741B2 (ja)	2013-06-26	アンドラスト／グルココルチコイドの併用
WO2002019995A2 (en)	2002-03-14	Pharmaceutical combination containing salmeterol and fluticasone